Company intelligence / Profile preview

RapidDx

Irvine, California, United Statesrapiddx.net ↗

Ownership: Private
Development stage: Other

Overview

The company is developing a patented handheld saliva-based diagnostic device using lateral flow immunochromatography to rapidly detect salivary biomarkers for early assessment of neurological and psychiatric conditions. The platform aims to deliver results within minutes at the point of care. No clinical trial results or regulatory approvals have been announced; the product remains in development.[4][5]

Therapeutic areas: PsychiatryNeurology
Modalities: DeviceLateral flow immunochromatography technology (for biomarker detection)
Industry: Molecular Diagnostics

Partnerships

Collaborates with scientists and regulatory agencies for product design and validation

Beyond the preview

Go deeper on RapidDx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RapidDx.

Explore the full profile